{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fujita N"],"funding":["Japan Society for the Promotion of Science"],"pagination":["1506-1517"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12503203"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(10)"],"pubmed_abstract":["<h4>Objectives</h4>To evaluate the effects of renal impairment at the time of second-line tyrosine kinase inhibitor (TKI) therapy initiation and rapid renal function decline during first-line immuno-oncology (IO) combination therapy on metastatic renal cell carcinoma (mRCC) patients treated with second-line TKIs.<h4>Methods</h4>This multicenter retrospective study included 243 mRCC patients treated with first-line IO combination therapy, followed by second-line TKI therapy. Patients were divided into three groups using the estimated glomerular filtration rate (eGFR; mL/min/1.73 m<sup>2</sup>) at the time of second-line TKI therapy initiation: eGFR ≥ 60, 30 ≤ eGFR < 60, and eGFR < 30. The eGFR slope during first-line IO combination therapy was calculated using eGFR measurements when initiat"],"journal":["International journal of urology : official journal of the Japanese Urological Association"],"pubmed_title":["Impact of Impaired Renal Function on the Efficacy and Safety of Second-Line Tyrosine Kinase Inhibitor Therapy After First-Line Immuno-Oncology Combination Therapy in Metastatic Renal Cell Carcinoma: A Japanese Multicenter Retrospective Study."],"pmcid":["PMC12503203"],"funding_grant_id":["19K18603"],"pubmed_authors":["Fujita N","Kojima T","Osawa T","Sazuka T","Tanaka H","Kawasaki Y","Miyake M","Japanese Urological Oncology Group","Kitamura H","Miyake H","Tomida R","Fujita K","Bando Y","Kato T","Hakakeyama S","Kandori S","Ueda K","Goto K","Yamana K","Matsushita Y","Numakura K"],"additional_accession":[]},"is_claimable":false,"name":"Impact of Impaired Renal Function on the Efficacy and Safety of Second-Line Tyrosine Kinase Inhibitor Therapy After First-Line Immuno-Oncology Combination Therapy in Metastatic Renal Cell Carcinoma: A Japanese Multicenter Retrospective Study.","description":"<h4>Objectives</h4>To evaluate the effects of renal impairment at the time of second-line tyrosine kinase inhibitor (TKI) therapy initiation and rapid renal function decline during first-line immuno-oncology (IO) combination therapy on metastatic renal cell carcinoma (mRCC) patients treated with second-line TKIs.<h4>Methods</h4>This multicenter retrospective study included 243 mRCC patients treated with first-line IO combination therapy, followed by second-line TKI therapy. Patients were divided into three groups using the estimated glomerular filtration rate (eGFR; mL/min/1.73 m<sup>2</sup>) at the time of second-line TKI therapy initiation: eGFR ≥ 60, 30 ≤ eGFR < 60, and eGFR < 30. The eGFR slope during first-line IO combination therapy was calculated using eGFR measurements when initiat","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-04T06:27:02.584Z","creation":"2026-05-06T03:13:05.348Z"},"accession":"S-EPMC12503203","cross_references":{"pubmed":["40613546"],"doi":["10.1111/iju.70172"]}}